NCT03734926Unknown1 期
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of ZSP1241 in Participants With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Safety and tolerability of ZSP1241 in single dose ascending (SAD) and multiple dose ascending (MAD) as measured by assessment of maximum tolerated dose (MTD), dose limiting toxicity (DLT) and treatment emergent adverse events (TEAEs)
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1241 in participants with hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants are required to meet all the criteria below in order to be included in the trial:
- •Male or female patient, aged 18 ~ 75 years.
- •Confirmed diagnosis of advanced solid tumors by histological or cytological examination, participants have no effective standard anticancer therapy available or is intolerant to standard anticancer therapy.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Participants with at least 1 measurable tumor lesion based on RECIST 1.
- •Recovery from past medical history of adverse reactions (excluding alopecia and neurotoxicity) caused by radiotherapy and/or chemotherapy to NCI CTCAE 5.0 Grade ≤ 1 or baseline level.
- •Life expectancy ≥ 12 weeks.
- •Adequate organ function, defined by the following laboratory results, to be obtained prior to enrollment:
- •Bone marrow function: ANC≥1.5×109/L; HB≥90 g/L; PLT≥75×109/L. Liver function: ALT≤2.5×ULN, AST≤2.5×ULN, ALP≤2.5×ULN, TBIL≤1.5×ULN; ALT≤5×ULN, AST≤5×ULN (For participants with liver focal masses and metastasis).
- •Renal function: creatinine≤1.5×ULN; CL≥ 50 mL/min. Coagulation function: INR≤1.5×ULN; INR≤2.3×ULN (For participants with liver focal masses and metastasis).
- •Child-Pugh class A (only for hepatocellular carcinoma and cholangiocarcinoma).
- •Participants (including partners) who have no gestation plans and are willing to follow reliable contraceptive measures during the study and until 8 months after the last dosing.
- •Participants with voluntarily signature Informed Consent Form (ICF) prior to screening.
排除标准
- •Eligible participants must not meet any of the following exclusion criteria:
- •Participants who have intracranial tumor and/or brain metastases with clinical symptoms needed treatment are ineligible not including the following :
- •recovery from the therapy (including radiotherapy and/or surgery) 4 weeks before enrollment.
- •participants with intracranial tumor who are clinically stable during screening and enrollment, no need to medication by hormone or anticonvulsants, and predicted to be clinically stable during the study.
- •Participants who suffer from chronic and active infective diseases and require systemic antibiotic, antifungal, or antiviral treatment except concomitant antiviral systemic therapy for chronic hepatitis B or C.
- •Participants with dysphagia.
- •Participants with incontrollable hydrops in third lumen such as malignant pleural effusion and ascites.
- •Participants with history of pulmonary fibrosis or interstitial pneumonia including pneumoconiosis and radiation pulmonary fibrosis beyond radiation field.
- •Participants who suffer from irritable bowel syndrome and need medication.
- •Participants with any clinically significant gastrointestinal abnormalities such as Crohn's disease, ulcerative colitis and subtotal gastrectomy.
- •Participants with major surgery in recent 4 weeks or active peptic ulcer disease or unrecovered wound.
- •Participants with history of myocardial infarction or congestive heart-failure (CHF) at NYHA≥3 level within 6 months prior to enrollment.
- •Participants with LVEF<50% during screening.
- •Participants with QTcF prolongations in ECG baseline ( QTcF>450ms for males or QTcF>470ms for females) or high risk factors leading to QT intervals prolonging (including hypokalemia, familial QT interval prolongation syndrome) or a history of uncontrollable blood pressure or a history of severe or uncontrollable ventricular arrhythmia such as two or three degree atrioventricular block.
- •Participants with medications known as QTc prolongation or TDP ventricular tachycardia inducer or strong inhibitors and inducers of CYP3A4 not less than 5 days or 5 half-times before first dosing ZSP
- •Participants with history of most recently chemotherapy, radiotherapy, or non-antibody antitumor biologics within 4 weeks prior to the first ZSP1241 treatment and last time medication of nitrosoureas, mitomycin C or doxorubicin within 6 weeks and latest usage of antibody antitumor biologics within 4 weeks.
- •Participants with current or prior retinal detachment or presently confirmed diagnosis keratopathy including but not limited to bullous keratopathy, calcific band keratopathy, corneal abrasion, keratohelcosis, keratitis and so on.
- •Participants with history of autoimmune disease.
- •Pregnant or nursing women.
- •Participants who, in the judgment of the investigator, will be unfit for the study. ( For reasons such as poor compliance, unsuitable for venous catheterization and so on)
研究组 & 干预措施
Part 1
Experimental
Participants with advanced solid tumors including hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.
干预措施: ZSP1241 (Drug)
Part 2 Cohort A
Experimental
Participants with hepatocellular carcinoma.
干预措施: ZSP1241 (Drug)
Part 2 Cohort B
Experimental
Participants with gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumor.
干预措施: ZSP1241 (Drug)
结局指标
主要结局
Safety and tolerability of ZSP1241 in single dose ascending (SAD) and multiple dose ascending (MAD) as measured by assessment of maximum tolerated dose (MTD), dose limiting toxicity (DLT) and treatment emergent adverse events (TEAEs)
时间窗: At Day 7 for SAD Part and At day 28 after for MAD part
Participant with TEAEs assessed by CTCAE V5.0
次要结局
- Time to progression (TTP).(Screening, Day 28 of Cycle 1 (28 days), then every 6 weeks for hepatocellular carcinoma or 8 weeks for other advanced solid tumors, until disease progression or discontinuation from study (up to 18 months).)
- Overall response rate (ORR).(Screening, Day 28 of Cycle 1 (28 days), then every 6 weeks for hepatocellular carcinoma or 8 weeks for other advanced solid tumors, until disease progression or discontinuation from study (up to 18 months).)
- Cmax of ZSP1241(Protocol-defined time points during Cycles 0 (7 days) and 1 (28 days) of treatment per subject.)
- Tmax of ZSP1241(Protocol-defined time points during Cycles 0 (7 days) and 1 (28 days) of treatment per subject.)
- Cmin of ZSP1241(Protocol-defined time points during Cycles 0 (7 days) and 1 (28 days) of treatment per subject.)
- AUC0-t of ZSP1241(Protocol-defined time points during Cycles 0 (7 days) and 1 (28 days) of treatment per subject.)
- t½ of ZSP1241(Protocol-defined time points during Cycles 0 (7 days) and 1 (28 days) of treatment per subject.)
- Cl/F of ZSP1241(Protocol-defined time points during Cycles 0 (7 days) and 1 (28 days) of treatment per subject.)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid TumorsMedulloblastomaAdenocarcinoma of Esophagogastric JunctionSmall Cell Lung CancerNeuroendocrine NeoplasmBasal Cell CarcinomaGlioblastomaNCT03734913Guangdong Zhongsheng Pharmaceutical Co., Ltd.65
撤回
1 期
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)Bladder CancerNCT05259397Pfizer
尚未招募
1 期
Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy VolunteersChronic Spontaneous UrticariaNCT04404023UBP Greater China (Shanghai) Co., Ltd15
已完成
1 期
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU PatientsUrticaria ChronicNCT03632291United BioPharma15
进行中（未招募）
1 期
A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasNCT06226571Syndax Pharmaceuticals96